MNG Laboratories, an Atlanta-based neurogenetic testing company, is pleased to announce that it has signed a Distribution Agreement with Pronto Diagnostics, a leading Israeli genomics company, to exclusively market its complete line of Clinical RNA Sequencing Services in Israel.
The RNA Sequencing Services portfolio includes the MNG Transcriptome™ complete RNA transcriptome sequencing, Gene-Specific RNA Sequencing for the analysis of one or up to five genes for variant investigation following a report with a VUS identified in a splice site or intronic region and Panel-Specific RNA Sequencing which is transcriptome analysis of a target set of genes included in a targeted next generation sequencing panel.
“We are excited to add RNA sequencing services to our portfolio of testing services in Israel. We chose MNG due to their experience and leadership in rare disease diagnostics. Having the ability to offer this important set of tests helps us to ensure we offer the best diagnostic tools to our clients”, noted Nir Navot, CEO of Pronto Diagnostics.
A recent study in Science Translational Medicine reported that RNA sequencing was able to provide a diagnosis in 35% of patients with muscle disorders that could not be diagnosed by DNA sequencing alone (PMID: 28424332) and patients with other types of disorders are also likely to benefit from this testing. Additionally, this testing can be used to determine what effect, if any, variants of uncertain significance (VUS) may have on transcription.
“This partnership with Pronto is an important addition to the expansion strategy at MNG to bring our portfolio of world class neurogenetic testing to the global rare disease diagnostic market,” noted Humberto Huerta, Senior Director of Business Development at MNG.
Under the Distribution Agreement, testing will be performed at MNG’s CLIA and CAP-accredited laboratory and a clinical report will be delivered in as fast as 2-4 weeks.
Source – BusinessWire